Aggrastat

(Tirofiban)

ApprovedSmall molecule

Aggrastat is a small molecule that works as a Integrin Alpha-Iib/beta-3 Inhibitor.[2] It is being used across 12 indications, with its most advanced program in Approved.[1]

Aggrastat is one of 256 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

255

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

StrokeNot yet recruiting

Renal InsufficiencyApproved

Recurrent ThrombophlebitisActive, not recruiting

Stroke, AcuteRecruiting

Ischemic Stroke, AcuteNot yet recruiting

Acute Myocardial InfarctionCompleted

Coronary Artery DiseaseUnknown status

Ischemic StrokeActive, not recruiting

Acute Coronary SyndromeTerminated

Subarachnoid HemorrhageNot yet recruiting

StrokePhase 3

Not yet recruiting

Renal InsufficiencyApproved

Approved

Recurrent ThrombophlebitisApproved

Active, not recruiting

Stroke, AcutePhase 3

Recruiting

Ischemic Stroke, AcuteApproved

Not yet recruiting

Acute Myocardial InfarctionApproved

Completed

Coronary Artery DiseaseApproved

Unknown status

Ischemic StrokeApproved

Active, not recruiting

Acute Coronary SyndromeApproved

Terminated

Subarachnoid HemorrhagePhase 2

Not yet recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Aggrastat

MMedicure

Approved

2 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cerebrovascular Event

NCT06319846

Post-ApprovalRecruiting

STEMI

NCT06769256

N/ARecruiting

Ischemic Stroke

NCT06045156

Post-ApprovalRecruiting

Ischemic Stroke

NCT07290751

Q2 2027

N/ARecruiting

Ischemic Stroke

NCT07026318

Phase 3Not yet recruiting

Stroke

NCT07335107

Clinical

Trials by Indication[1]

Ischemic stroke4 trials

Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke

Recruiting·—·N/A·NCT07026318·716 enrolled

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

Recruiting·—·Phase 4·NCT07290751·976 enrolled

ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion

Active, not recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT05225961·240 enrolled

Show 1 more trial

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Recruiting·TThe First Hospital of Jilin University·N/A·NCT06045156·1,084 enrolled

Acute Coronary Syndrome3 trials

Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation

Terminated·—·Phase 4·NCT00445263·170 enrolled

Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT03114995·140 enrolled

Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

Unknown status·PPusan National University Yangsan Hospital·Phase 3·NCT01660373·100 enrolled

Acute Myocardial Infarction3 trials

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Completed·FFudan University·Phase 4·NCT02131220·362 enrolled

The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction

Completed·SSamsung Medical Center·Phase 4·NCT00611169·40 enrolled

GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction

Completed·HHospices Civils de Lyon·Phase 4·NCT00538317·320 enrolled

Percutaneous Coronary Intervention3 trials

The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention

Unknown status·—·Phase 4·NCT00407771·44 enrolled

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Terminated·IInova Health Care Services··NCT03048019·10 enrolled

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

Withdrawn·MMedicure·Phase 3·NCT01245725

Aneurysm2 trials

Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban

Unknown status·LLu Hua·Phase 4·NCT05841147·70 enrolled

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Completed·—·Phase 2/3·NCT06238115·192 enrolled

20 more indications

Acute2 trials

Treating Acute MI Patients With Aggrastat on Their Way to Hospital

Unknown status·TThe Baruch Padeh Medical Center, Poriya·Phase 4·NCT00300833·200 enrolled

Shanghai Registry of Acute Coronary Events

Terminated·SShanghai Jiao Tong University School of Medicine··NCT00713557·20,000 enrolled

STEMI2 trials

Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden

Recruiting·HHenan Institute of Cardiovascular Epidemiology·Phase 4·NCT06769256·300 enrolled

Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT03797729·500 enrolled

Stroke2 trials

Intravenous Tirofiban After Delayed Thrombolysis in Stroke

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07111806·852 enrolled

Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion

Not yet recruiting·—·Phase 3·NCT07335107·564 enrolled

TED1 trial

Tirofiban for Patients Treated With Alteplase

Terminated·—·Phase 2/3·NCT03357133·30 enrolled

Function1 trial

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

Completed·MMedicure·Phase 1·NCT01766154·25 enrolled

Coronary Artery Disease1 trial

Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease

Unknown status·SSecond Hospital of Jilin University·Phase 4·NCT02294994·1,000 enrolled

Subarachnoid Hemorrhage1 trial

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

Not yet recruiting·—·Phase 1/2·NCT07493577·82 enrolled

Clopidogrel1 trial

Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance

Completed·UUniversità degli Studi di Ferrara·Phase 4·NCT00398463·263 enrolled

Coronary Artery Bypass1 trial

The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

Unknown status·PPrince Sultan Cardiac Center, Adult Cardiology Department.·Phase 3·NCT01598337·200 enrolled

ESS1 trial

Tirofiban After Successful MT Recanalization in AIS

Completed·XXiang Luo·Phase 2/3·NCT06265051·1,380 enrolled

Myocardial Infarction1 trial

Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse

Completed·UUniversità degli Studi di Ferrara·Phase 3·NCT01336348·100 enrolled

Randomized1 trial

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT02978040·122 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Completed·PPeking Union Medical College Hospital·Phase 3·NCT06037889·516 enrolled

Cerebrovascular Event1 trial

Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）

Recruiting·—·Phase 3·NCT06319846·4,674 enrolled

Enoxaparin1 trial

Tirofiban and Enoxaparin in High Risk Coronary Intervention

Completed·—·Phase 4·NCT00790387·60 enrolled

COVID-191 trial

Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

Completed·UUniversity of Milan·Phase 2·NCT04368377·5 enrolled

Stroke, Acute Ischemic1 trial

Intravenous Adjuvant With Tirofiban Versus Thrombolysis Before Mechanical Thrombectomy in Acute Ischemic Stroke Patients With Large Vessel Occlusion: a Multicenter, Open Label, Randomized Controlled Trial.

Completed·XXinqiao Hospital of Chongqing·Preclinical·NCT05728333·1,014 enrolled

Ischemic Stroke, Acute1 trial

Efficacy and Safety of Tirofiban Combined With Aspirin in Moderate Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Not yet recruiting·XXinqiao Hospital of Chongqing·Approved·NCT07760922·1,168 enrolled

Stroke, Acute1 trial

Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging

Recruiting·WWeifang Medical University·Phase 3·NCT07379190·458 enrolled

Unspecified3 trials

Safety of High-dose Tirofiban During Coronary Angioplasty

Completed·—·Phase 4·NCT00566891·2,000 enrolled

Tirofiban in Stenting for Long Coronary Lesion

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01498003·748 enrolled

Intracoronary Tirofiban on No-Reflow Phenomena

Completed·TTC Erciyes University·Phase 4·NCT02054000·162 enrolled

Regulatory

FDA Approval Timeline[4]

May 14, 1998

AGGRASTAT

NDA NDA020912

May 17, 2002

AGGRASTAT

NDA NDA020913

Sources

References

[1]
ClinicalTrials.gov — 40 trial records for Tirofiban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tirofiban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tirofiban. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020913). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Medicure company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Integrin Alpha-Iib/beta-3 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedicure

Aggrastat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Ischemic stroke4 trials

Acute Coronary Syndrome3 trials

Acute Myocardial Infarction3 trials

Percutaneous Coronary Intervention3 trials

Aneurysm2 trials

Acute2 trials

STEMI2 trials

Stroke2 trials

TED1 trial

Function1 trial

Coronary Artery Disease1 trial

Subarachnoid Hemorrhage1 trial

Clopidogrel1 trial

Coronary Artery Bypass1 trial

ESS1 trial

Myocardial Infarction1 trial

Randomized1 trial

Efficacy and Safety1 trial

Cerebrovascular Event1 trial

Enoxaparin1 trial

COVID-191 trial

Stroke, Acute Ischemic1 trial

Ischemic Stroke, Acute1 trial

Stroke, Acute1 trial

Unspecified3 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News